Physician profile
Guy L Mintz
NPI 1508869884
$71,267.01
in general payments reported to CMS, 2019-2025
16 companies · $2,287 in 2025
The $2,287 reported for 2025 was more than what 85% of Cardiovascular Disease providers received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $17K · 2020: $10K · 2021: $7,661 · 2022: $6,921 · 2023: $12K · 2024: $15K · 2025: $2,287.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $22K · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $4,450 · Food and Beverage: $2,186 · Travel and Lodging: $516 · Education: $25.70.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $21,877.50 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $4,450.00 |
| Food and Beverage | $2,186.35 |
| Travel and Lodging | $515.94 |
| Education | $25.70 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Esperion Therapeutics, INC. | $17,333.46 | 2020-2025 | Nexletol |
| Novartis Pharmaceuticals Corporation | $13,383.81 | 2020-2024 | Leqvio |
| Janssen Pharmaceuticals, INC | $12,844.33 | 2019-2023 | Xarelto |
| Regeneron Pharmaceuticals, INC. | $6,239.19 | 2019-2025 | Evkeeza |
| Novo Nordisk INC | $6,200.00 | 2023 | |
| Merck Sharp & Dohme LLC | $5,804.14 | 2024-2025 | |
| Regeneron Healthcare Solutions, INC. | $4,171.35 | 2019 | |
| Kaneka Medical America LLC | $3,250.00 | 2023-2025 | Apheresis Machine |
| Sanofi-Aventis U.S. LLC | $749.00 | 2019 | |
| Amgen INC. | $576.94 | 2022-2025 | Repatha, Repatha |
| Edwards Lifesciences Corporation | $365.96 | 2019-2025 | Sapien 3 Ultra Resilia |
| Medtronic, INC. | $127.57 | 2025 | Corevalve Evolut R |
| Heartflow, INC. | $119.04 | 2020 | |
| Abbott Laboratories | $70.23 | 2021 | |
| Atricure, INC. | $19.09 | 2022 |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Akcea Therapeutics, INC. | $12.90 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Guy Mintz listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.